Market Cap (In CNY)
295.68 Billion
Revenue (In CNY)
22.81 Billion
Net Income (In CNY)
4.3 Billion
Avg. Volume
27.36 Million
- Currency
- CNY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 35.51-57.53
- PE
- -
- EPS
- -
- Beta Value
- 0.293
- ISIN
- CNE0000014W7
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Hong Bin Dai
- Employee Count
- -
- Website
- https://www.hrs.com.cn
- Ipo Date
- 2000-10-18
- Details
- Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
More Stocks
-
4651Sanix Incorporated
4651
-
DYAdynaCERT Inc.
DYA
-
6797
-
BML-PLBank of America Corporation
BML-PL
-
ANDHRSUGARThe Andhra Sugars Limited
ANDHRSUGAR
-
FACORALLFacor Alloys Limited
FACORALL
-
ISI
-
SRBIFSerabi Gold plc
SRBIF